Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
ALT Stock Chart & Stats
$4.05
$0.16(2.19%)
At close: 4:00 PM EST
$4.05
$0.16(2.19%)
Day’s Range― - ―
52-Week Range$2.90 - $11.16
Previous CloseN/A
Volume1.55M
Average Volume (3M)2.72M
Market Cap
$357.44M
Enterprise Value$148.02M
Total Cash (Recent Filing)$183.10M
Total Debt (Recent Filing)$15.85M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Nov 06, 2025EPS Estimate
-0.27Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding88,257,256
10 Day Avg. Volume2,528,306
30 Day Avg. Volume2,716,221
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue7.40K
Enterprise Value/Gross Profit-14.80K
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$19.75Price Target Upside387.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Leadership And StrategyWith experienced leadership, a clear strategy, and compelling data in hand, Altimmune is positioned for a key inflection point.
Market PotentialPemvidutide may generate peak annual revenues of over $1B in MASH if approved.
Regulatory AdvancementsRegulatory commentary was constructive: CEO Garg reiterated that the FDA remains motivated to move away from biopsy-based endpoints toward artificial intelligence (AI)-assisted histologic reads and non-invasive tests such as vibration-controlled transient elastography (VCTE) and iron-corrected T1 (cT1).
Bears Say
Efficacy ConcernsInvestors will likely have to wait for years before lingering questions about the treatment's efficacy are resolved.
Market CompetitionPemvidutide lacks clear differentiation in the increasingly competitive MASH market.
Regulatory HurdlesNon-invasive tests cannot form the basis of regulatory approval at this time.
Altimmune News
ALT FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was $2.90 and its highest was $11.16 in the past 12 months.
What is Altimmune Inc’s market cap?
Altimmune Inc’s market cap is $357.44M.
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Nov 06, 2025 which is in 2 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Aug 12, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.336 by $0.066.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -0.27.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 88,257,256 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.336. Following the earnings report the stock price went up 7.101%.
Which hedge fund is a major shareholder of Altimmune Inc?
Currently, no hedge funds are holding shares in ALT
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (387.65% Upside)
$19.75 (387.65% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 142.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.91%
12-Months-Change
Fundamentals
Return on Equity
-55.91%
Trailing 12-Months
Asset Growth
9.81%
Trailing 12-Months
Company Description
Altimmune Inc
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of infectious diseases, liver diseases, and cancer. The company is primarily engaged in creating intranasal and oral therapies that aim to stimulate immune responses without the need for injections. Its core products include ALT-801, an immunotherapeutic for obesity and metabolic disease, and a range of other candidates targeting hepatitis B and various cancers.
ALT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a largely positive outlook for Altimmune, emphasizing significant advances in clinical trials, particularly for NASH, and a strong financial position. However, challenges remain in achieving statistical significance for fibrosis improvement and navigating regulatory pathways for noninvasive testing.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$19.75
▲(387.65% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.71% Insiders
10.64% Mutual Funds
0.11% Other Institutional Investors
76.09% Public Companies and Individual Investors